p53 Down-Regulates Phosphatase and Tensin Homologue Deleted on Chromosome 10 Protein Stability Partially through Caspase-Mediated Degradation in Cells with Proteasome Dysfunction
Open Access
- 15 June 2006
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 66 (12) , 6139-6148
- https://doi.org/10.1158/0008-5472.can-06-0772
Abstract
There has been intense investigation regarding the interaction between the phosphatase and tensin homologue deleted on chromosome 10 (PTEN) and p53 tumor suppressors. p53 has been shown to up-regulate PTEN expression as a transcriptional activator. However, clinical observations by immunohistochemistry studies indicate that significant increases in p53 protein levels coexist with reduced or absent expression of PTEN protein in a variety of neoplasias. In this study, we propose a mechanism that begins to explain how p53 can both up-regulate and down-regulate PTEN. We have found that PTEN protein is down-regulated under proteasome dysfunction induced by proteasome inhibitor MG132 in both human lymphoblast cells and MCF7 cells. The reduction of PTEN is coincident with elevated p53 protein levels and the association between PTEN and p53 but independent of its phosphatase activities. Quantitative reverse transcription-PCR indicates that proteasome inhibition does not reduce PTEN message levels but affects PTEN protein stability. The p53 inhibitor, pifithrin-α, is able to attenuate the effect of proteasome inhibition. Using ectopic expression studies in p53-null mouse embryonic fibroblasts and p53/PTEN-null PC3 cells, we show that PTEN is more stable in p53-null cells compared with p53-expressing cells. Inhibition of caspases, the downstream targets of p53, particularly caspase-3, can partially restore the stability of PTEN. This study provides the first evidence that p53 is able to down-regulate PTEN protein stability in stressed cells. Our study sheds some light on the mechanisms that regulate PTEN protein stability, which is important to fully elucidate to comprehend the broad neoplastic manifestations of Cowden syndrome/Bannayan-Riley-Ruvalcaba and sporadic cancers. (Cancer Res 2006; 66(12): 6139-48)Keywords
This publication has 31 references indexed in Scilit:
- PTEN Autoregulates Its Expression by Stabilization of p53 in a Phosphatase-Independent MannerCancer Research, 2006
- Increased Protein Expression of the PTEN Tumor Suppressor in the Presence of Constitutively Active Notch-1Cell Cycle, 2005
- Loss of Tumor Suppressor p53 Decreases PTEN Expression and Enhances Signaling Pathways Leading to Activation of Activator Protein 1 and Nuclear Factor κB Induced by UV RadiationCancer Research, 2005
- PTEN expression elicited by EGR‐1 transcription factor in calyculin A‐induced apoptotic cellsJournal of Cellular Biochemistry, 2004
- Inhibition of p53-mediated transcriptional responses by mithramycin AOncogene, 2004
- The proteasome inhibitor, MG132, promotes the reprogramming of translation in C2C12 myoblasts and facilitates the association of hsp25 with the eIF4F complexEuropean Journal of Biochemistry, 2004
- Transcriptional repression of E2F gene by proteasome inhibitors in human osteosarcoma cellsBiochemical and Biophysical Research Communications, 2004
- PTEN: One Gene, Many SyndromesHuman Mutation, 2003
- p53-dependent apoptosis induced by proteasome inhibition in mammary epithelial cellsCell Death & Differentiation, 2001
- Transcriptional squelching by ectopic expression of E2F-1 and p53 is alleviated by proteasome inhibitors MG-132 and lactacystinOncogene, 1997